Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01829958
First received: April 8, 2013
Last updated: November 10, 2014
Last verified: November 2014

April 8, 2013
November 10, 2014
April 2013
April 2016   (final data collection date for primary outcome measure)
Toxicity Assessment [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
Hospitalization during or within 30 days following chemotherapy Dose delay or reduction to a dose intensity ≤80% of the planned dose intensity. Dose reductions occurring prior to cycle 1 of chemotherapy will be counted as events. Discontinuation of chemotherapy due to toxicity Grade 3 or higher non-hematologic toxicity Grade 4 or higher hematologic toxicity. Using the NCI CTCAE v4.0 toxicity grading
Same as current
Complete list of historical versions of study NCT01829958 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy

This study will evaluate the ability of a largely self-administered geriatric assessment (GA) to predict toxicity in non-Hodgkin Lymphoma (NHL) patients ≥60 years old receiving chemotherapy or chemoimmunotherapy.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Non Hodgkin Lymphoma (NHL)
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Drug: rituximab
  • Drug: prednisone
  • Behavioral: Geriatric Assessment
  • Experimental: Pre-Phase Arm
    They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol.
    Interventions:
    • Drug: rituximab
    • Drug: prednisone
    • Behavioral: Geriatric Assessment
  • Experimental: Geriatric Assessment (GA) only arm
    Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic.
    Intervention: Behavioral: Geriatric Assessment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
April 2016
April 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

Subjects meeting the following criteria will be eligible for enrollment in the study (unless excluded):

  • ≥60 years old
  • Pathologically confirmed NHL.
  • Must meet criteria for initiation of treatment; consisting of:
  • Aggressive histology, or
  • Indolent histology with one of the following markers of large tumor burden (67):
  • Any nodal or extranodal tumor mass ≥7cm in greatest dimension
  • ≥3 nodal masses that are each ≥3 cm in greatest dimension
  • Systemic symptoms
  • Cytopenias (leukocytes <1 × 109/L and/or platelets ,100 × 109/L)
  • Substantial splenomegaly
  • Serous effusion (plural effusion or peritoneal ascites)
  • Orbital or epidural involvement
  • Ureteral compression
  • Leukemic phase (malignant cells ≥5 x 109/L)
  • Must be starting a new chemotherapy regimen
  • Fluent in English (because not all components of the GA have been validated in other languages)
  • Able to provide informed consent

In addition to the above, subjects meeting the following criteria will be enrolled in the pre-phase arm of the study, until the accrual target for that arm is reached:

  • Age ≥ 70 years OR KPS ≤ 70
  • Pathologically confirmed diagnosis of DLBCL, with or without simultaneous or antecedent indolent lymphoma.
  • Previously untreated for DLBCL
  • Intended initial treatment to include ≥2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days. (4, 70)

Exclusion Criteria:

Subjects meeting the following criteria will be excluded from enrollment in the study:

  • Enrollment in a Phase I trial
  • Previously enrollment in this study
  • Patients scoring ≥ 11 on the BOMC (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt Subjects meeting the following criteria will be excluded from enrollment in the pre-phase arm of the study, but may be included in the GA only arm.
  • Contraindication to use of rituximab or prednisone including:
  • Uncontrolled diabetes mellitus
  • Systemic fungal infection
  • Evidence of active hepatitis B infection (i.e. patients testing positive hepatitis B surface antigen or viral DNA by PCR analysis) will be excluded. Patients with evidence of past infection without active viremia (i.e. positive hepatitis B core antibody, negative hepatitis B surface antigen and negative hepatitis B DNA PCR) will be treated with entecavir as per institutional guidelines and may be included in the study.
  • History of any serious adverse reaction to either a corticosteroid or rituximab not including rituximab infusion reactions ≤ Grade 3.
  • Patients enrolled on another clinical trial which prohibits the use of pre-phase therapy or any of its components.
Both
60 Years and older
No
Contact: Paul Hamlin, MD 212-639-6143
Contact: Andrew Zelenetz, MD, PhD 212-639-2656
United States
 
NCT01829958
13-028
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
Not Provided
Principal Investigator: Paul Hamlin, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP